Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA with PCV20 Coadministration in Adults ≥60 Years
2022-501988-40-00Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A and Streptococcus pneumoniae type 19A capsular polysaccharide antigen in respiratory syncytial virus disease (RSV) and pneumococcal disease (3 arms), sponsored by GSK. Primary endpoints: Opsonophagocytic antibody titers for each PCV20 pneumococcal serotype - between-group GMT ratio, RSV-A neutralizing antibody titers - between-group GMT ratio and 1 more. Started Jul 2023; status: completed.
02
Drugs
GSK3003899AStreptococcus pneumoniae type 19A capsular polysaccharide antigen
03
Conditions
respiratory syncytial virus disease (RSV)pneumococcal disease
Beyond the preview
Go deeper on 2022-501988-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501988-40-00.